By Chris Wack

 

Precigen Inc. said the U.S. Food and Drug Administration has cleared its investigational new drug application to initiate the Phase 1/1b clinical trial of PRGN-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive hematological and solid tumors.

The company said its PRGN-3007 is a first-in-class investigational therapy based on the next generation of its UltraCAR-T platform and incorporates intrinsic programmed cell death protein 1 blockade.

This first-in-human study of PRGN-3007 will be conducted in collaboration with the H. Lee Moffitt Cancer Center & Research Institute.

The Phase 1/1b clinical trial is designed to evaluate the safety and efficacy of PRGN-3007 in patients with advanced ROR1(+) hematological and solid tumors.

Precigen shares were up 8% to $4.93 in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

October 26, 2021 08:34 ET (12:34 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Precigen (NASDAQ:PGEN)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Precigen Charts.
Precigen (NASDAQ:PGEN)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Precigen Charts.